Top In Vivo Gene Therapy Companies in China

WuXi AppTec is a global leader in providing R&D and manufacturing services, specifically highlighting their integrated solutions that accelerate the development of cell and gene therapies. Notably, they have received FDA approval to manufacture Iovance's AMTAGVI™ for advanced melanoma, underscoring their capabilities in this innovative treatment area.

GeneMedi Vision is focused on developing innovative solutions for the therapeutics and diagnostics industry, emphasizing their expertise in next-generation gene therapy. Their GTU and G-NEXT programs utilize advanced AAV design and state-of-the-art manufacturing to address the industry's needs for effective gene therapy vectors.

Innoforce specializes in the innovation and global supply of plasmid DNA and RNA, making it a key player in the field of gene therapy. With extensive experience in GMP manufacturing and CDMO services, the company supports advanced therapy projects from R&D to commercialization.

PackGene Biotech is a leader in gene therapy delivery, specializing in AAV vectors, which are crucial for in vivo gene therapy applications. Their comprehensive services include vector design and construction, enhancing AAV production to meet the needs of clinical projects.

Evive Biotech is focused on developing innovative biological therapies, including their advanced drug candidates targeting oncology, inflammatory, and metabolic diseases. Their commitment to novel treatments is evident in their broad product pipeline, which includes a candidate for chemotherapy-induced neutropenia.

Pacific GeneTech focuses on innovative biotechnological solutions, including the development of next-generation vaccines. Their collaboration with leading research institutions highlights their commitment to advancing health through effective delivery systems.

Novogene utilizes advanced sequencing technologies from top providers, ensuring high-quality NGS data that is crucial for genomics research. With the largest sequencing capacity globally, Novogene is well-equipped to support in vivo gene therapy studies through its optimized processes and state-of-the-art facilities.

Gracell Biotechnologies is focused on developing innovative CAR-T cell therapies, which are a form of gene therapy that targets cancer and autoimmune diseases. Their clinical-stage pipeline emphasizes fast and effective responses through advanced cell therapy techniques.

BrainVTA specializes in high-quality viral preparation services, which are crucial for in vivo gene therapy research. Their expertise in providing high-titer viral preparations supports advancements in life science research, particularly in the context of gene therapy.

CARsgen is a biopharmaceutical company focused on developing innovative cell therapies, including its lead candidate, zevorcabtagene autoleucel, a CAR T-cell product targeting multiple myeloma. The company has established robust manufacturing capabilities for producing plasmids, lentiviral vectors, and CAR T cells, which are essential for advancing in vivo gene therapy approaches.